Please ensure Javascript is enabled for purposes of website accessibility

Why Axsome Therapeutics Stock Is Crashing Today

By George Budwell – Aug 9, 2021 at 11:28AM

Key Points

  • Axsome's promising MDD drug candidate could take longer than expected to enter the market.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An unexpected regulatory setback is weighing on the biotech's shares today.

What happened

Shares of Axsome Therapeutics (AXSM -5.22%), a mid-cap biotech, are down by a hefty 41.4% as of 10:08 a.m. EDT Monday morning. The drugmaker's shares are tumbling today in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). 

Specifically, Axsome revealed during its 2021 second-quarter earnings release this morning that the U.S. Food and Drug Administration (FDA) had notified the company on July 30, 2021 that it has identified deficiencies within the drug's regulatory application that preclude discussion of labeling and post-marketing requirements at this time. A final decision on AXS-05's regulatory review for MDD is currently slated for Aug. 22, 2021.

A man covering his face while sitting in front of a laptop at a desk.

Image source: Getty Images.

So what

Wall Street expects AXS-05 to rake in over $1.3 billion in sales per year by the end of the current decade. With this sizable revenue stream now in question, it's not altogether surprising that some shareholders are hitting the exits today. That said, Axsome did note in its Q2 earnings release that the FDA has yet to communicate any specific details in regards to the application's deficiencies. In other words, shareholders might be making a mountain out of a molehill.  

Now what

Is Axsome's stock a bad-news buy? Bargain hunters may indeed want to take advantage of this sharp pullback in the biotech's share price today. Axsome, after all, has multiple irons in the fire outside of its lead product candidate, and this regulatory setback could prove to be nothing more than an unfortunate delay in AXS-05's ultimate approval for MDD. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics Stock Quote
Axsome Therapeutics
$70.84 (-5.22%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.